70.40
+10.00%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Caliway Biopharmaceuticals Co
Its shares trade on Taiwan Stock Exchange under the ticker 6919.TW. It has been listed since 26 December 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 38.0m and a net loss of TWD 351.4m. At that date it held total assets of TWD 301.9m and shareholders' equity of TWD 299.9m.
Caliway Biopharmaceuticals Co. Ltd. offers pharmaceutical services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2022-12-26. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. The company is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The firm's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Dec 2022
- Website
- caliway.com.tw ↗
Leadership
Pay as last reported
- Mr. Lu-Hui HsuChairman of the Board, Chief Strategy Officer, since 2012
- Ms. Yufang LingChief Executive Officer, Chief Research & Development Officer, Director, since 2012
- Ms. Xiaojing ShenCorporate Governance Officer
- Conglin WangHead of Accounting
- Huimin ZhangHead of Finance
- Mr. Quancheng QiuDirector
- Mr. Gaorong ZhangDirector
- Mr. Buren GuoIndependent Director
- Mr. Weili LinIndependent Director
- Mr. Xianli PengIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Caliway Biopharmaceuticals focuses on small molecule drugs like CBL-514 for non-surgical fat reduction and cellulite treatment.
- Caliway's drug pipeline includes CBA-539 for skin whitening and anti-aging in non-clinical research.
- Caliway generates revenue from health food sales in Taiwan and China through agents and distributors.
Weaknesses
- Caliway's drugs CBA-539, CBO-012, and CBF-520 are still in non-clinical research stages.
- Caliway's revenue relies solely on health food sales without pharmaceutical product sales yet.
- Caliway has no clinical stage drugs beyond CBL-514 in the second clinical stage.
Opportunities
- Caliway can advance CBL-514 from second clinical stage to market approval.
- Caliway may expand health food sales into new markets beyond Taiwan and China.
- Caliway could develop additional small molecule drugs for degenerative arthritis and obesity.
Threats
- Caliway faces competition from other pharmaceutical companies in the Health Care sector.
- Caliway's reliance on health food sales may limit growth potential without pharmaceutical product revenue.
- Caliway's non-clinical stage drugs could face delays or failures in clinical trials.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.